Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | beta galactosidase | 0.014 | 0.0103 | 0.0103 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0029 | 0.0029 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0043 | 0.0018 | 1 |
Echinococcus granulosus | beta galactosidase | 0.014 | 0.0103 | 0.0103 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0029 | 0.0033 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 0.0103 | 0.012 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0 | 0.5 |
Loa Loa (eye worm) | alpha-L-fucosidase | 0.9801 | 0.8592 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0 | 0.5 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.43 | 0.3758 | 1 |
Mycobacterium ulcerans | alpha-L-fucosidase | 1.1403 | 1 | 1 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.43 | 0.3758 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0043 | 0.0018 | 1 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | 1.1403 | 1 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0029 | 0.0029 |
Brugia malayi | Alpha-L-fucosidase family protein | 0.9801 | 0.8592 | 1 |
Schistosoma mansoni | alpha-l-fucosidase | 0.9801 | 0.8592 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.0029 | 0.0033 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0029 | 0.0033 |
Schistosoma mansoni | beta-galactosidase | 0.014 | 0.0103 | 0.012 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0029 | 0.0033 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 0.0103 | 0.012 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0029 | 0.0029 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0029 | 0.0029 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0029 | 0.0033 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.4668 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.